DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/03/3107-924-931$20.00
DMD 31:924-931, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, M.
Right arrow Articles by Gonzalez, Frank. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, M.
Right arrow Articles by Gonzalez, Frank. J.

IDENTIFICATION OF CYP1A2 AS THE MAIN ISOFORM FOR THE PHASE I HYDROXYLATED METABOLISM OF GENISTEIN AND A PRODRUG CONVERTING ENZYME OF METHYLATED ISOFLAVONES

Ming Hu, Kristopher Krausz, Jun Chen, Xia Ge, Jianqi Li, Harry L. Gelboin, and Frank. J. Gonzalez

Laboratory of Molecular Carcinogenesis (M.H., K.K., H.L.G.), Laboratory of Metabolism (M.H., K.K., F.J.G.) National Cancer Institute, National Institute of Health, Bethesda, Maryland; Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, Washington (M.H., J.C.); Department of Medicinal Chemistry, Shanghai Institute of Pharmaceutical Industries, Shanghai, China (X.G., J.L.)

This study determined the cytochrome P450 (P450) isoforms responsible for metabolism of isoflavones using human liver microsomes (HLM) and expressed P450s. The primary metabolite of genistein is 3'-OH-genistein, as identified with an authentic chemically synthesized standard. CYP1A2 was predominantly responsible for 3'-OH-genistein formation since its formation was inhibited (>50%, p < 0.05) by a monoclonal antibody specific for CYP1A2, was correlated with CYP1A2 activities of HLM, and was catalyzed by expressed CYP1A2. In addition to CYP1A2, CYP2E1 also catalyzed, although to a lesser extent, its formation. The contribution of these P450s to the formation of 3'-OH-genistein was also confirmed with a panel of expressed enzymes. Methylated isoflavones biochanin A, prunetin, and formononetin (10–100 µM) were rapidly converted by HLM and expressed CYP1A2 to more active genistein and daidzein. The conversion of biochanin A to genistein appears to be mainly mediated by CYP1A2 because of the strong correlation between the conversion rates and CYP1A2 activities in HLM. Thus, CYP1A2 is an effective prodrug-converting enzyme for less active methylated isoflavones. CYP1A2-catalyzed conversion of biochanin A to genistein (Km, 7.80 µM; Vmax, 903 pmol/min/mg of protein; Vmax/Km, 116 µl/min/mg of protein) was much faster than 3'-hydroxylation of genistein (Km, 12.7 µM and Vmax, 109 pmol/min/mg of protein; Vmax/Km, 8.6 µl/min/mg of protein). The interaction studies showed that genistein inhibited formation of acetaminophen from phenacetin with an IC50 value of 16 µM. Additional studies showed that phenacetin and genistein were mutually inhibitory. In conclusion, CYP1A2 and CYP2E1 metabolized genistein and CYP1A2 acted as prodrug-converting enzymes for other less active methylated isoflavones.


Address correspondence to: Dr. Ming Hu, Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA 99164-6510. Email: minghu{at}wsu.edu




This article has been cited by other articles:


Home page
J. Nutr.Home page
M. Cotterchio, B. A. Boucher, M. Manno, S. Gallinger, A. Okey, and P. Harper
Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk
J. Nutr., December 1, 2006; 136(12): 3046 - 3053.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Jia, J. Chen, H. Lin, and M. Hu
Disposition of Flavonoids via Enteric Recycling: Enzyme-Transporter Coupling Affects Metabolism of Biochanin A and Formononetin and Excretion of Their Phase II Conjugates
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1103 - 1113.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.